Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by Moocheeon Nov 01, 2015 9:29pm
207 Views
Post# 24249087

RE:No One Disputes

RE:No One DisputesFront and center. thanks for the post mate
sanspeine wrote: No one disputes forward guidance.
No one disputes that AMco was not a transformative acquisition
No one disputes the growth scenario for the next 5 years.
No one disputes that cash flows will be substantively above debt and interest repayments
No one disputes that being equity conservative, potential for future equity raises are robust.
No one disputes that 224 drugs represents one of the largest suite of drugs held by any pharma of any size.

So why is Concordia trading at just 1/3 of its recent former high?

Its a sideswipe  caused by poorly performing US hedge funds selecting the best performing sector and issueing or paying for the issue of distorting research reports that spooked the markets and made successful their shorting game plan.

Havent anyone noticed that not a single accusation has been proven nor will one ever be proven.

We have just been taken for a ride.
Very soon, the sharks will move on and this sector will return to its normal rating as the best investment performing niche.

Afterall, other than perhaps technology, what else has such fundamentals.

This coming week we shall see the beginning of the return to normality for healthcare and pharma stocks


<< Previous
Bullboard Posts
Next >>